XBiotech
XBIT
48 hedge funds and large institutions have $43.6M invested in XBiotech in 2016 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 20 increasing their positions, 10 reducing their positions, and 5 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 10
40% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 5
4% more funds holding
Funds holding: 46 → 48 (+2)
25% less capital invested
Capital invested by funds: $58.4M → $43.6M (-$14.8M)
98% less call options, than puts
Call options by funds: $15K | Put options by funds: $805K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.72M |
| 2 |
CCM
Cadian Capital Management
New York
|
+$2.05M |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$1.21M |
| 4 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$683K |
| 5 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$646K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IG
ING Group
Amsterdam,
Netherlands
|
-$1.12M |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$623K |
| 3 |
Goldman Sachs
New York
|
-$555K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$536K |
| 5 |
DekaBank Deutsche Girozentrale
Frankfurt,
Germany
|
-$376K |
XBIT Hedge Fund Activity: Q3 2016 in Review
48 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in XBiotech (XBIT) for Q3 2016, worth a combined $43.6M — down 25% from $58.4M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new XBIT positions and 5 closed out — a net gain of 2 holders — while 20 added to existing stakes and 10 trimmed.
The largest buyer was Vanguard Group, adding an estimated $2.72M. The largest seller was ING Group, exiting entirely with an estimated $1.12M sold.
- 48 institutional investors held XBiotech (XBIT) as of Q3 2016, up from 46 in Q2 2016.
- Funds reported $43.6M of XBiotech stock for Q3 2016, down 25% quarter-over-quarter.
- 7 funds opened new XBiotech positions in Q3 2016 and 5 closed out, a net change of +2 holders.
- The largest XBiotech buyer in Q3 2016 was Vanguard Group, an estimated $2.72M added.
- The largest XBiotech seller in Q3 2016 was ING Group, an estimated $1.12M sold.
Based on aggregated 13F filings for Q3 2016.